Drug Monitoring, Panel 1, Screen, Urine
Also known as: Prescription Drug Monitoring, Pain Management
Use
This test provides initial immunoassay-based screening of urine specimens for a wide range of commonly abused substances, enabling prompt detection of illicit or prescription drug use for clinical, occupational, or forensic purposes.
Special Instructions
Specimen is collected in a sterile urine container with at least 30 mL volume and submitted with a completed custody and control form; collected at Quest Diagnostics collection sites under standard procedures.
Limitations
As a screening immunoassay, results are presumptive; positive screens should be confirmed with a more specific method (e.g., GC‑MS or LC‑MS/MS). Cross-reactivity and false positives may occur.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
30 mL minimum
Minimum Volume
30 mL
Container
sterile container
Collection Instructions
Collect urine in sterile container—minimum 30 mL; for DOT collection, 45 mL. Submit with completed Custody and Control Form.